Building the future of medicine
How Canada is accelerating life sciences innovation through collaboration and capital

When BioNTech developed an effective mRNA molecule to fight covid-19, the German company still faced a critical challenge: how to deliver the fragile genetic material safely into human cells.
The solution emerged through an in-person introduction at an industry event, where BioNTech’s co-founder, Ugur Sahin, met the founders of Vancouver-based Acuitas Therapeutics. The company had been developing lipid nanoparticle (LNP) systems—microscopic balls of fat, each 700-times smaller than the width of a human hair—that could transport fragile genetic material into human cells. Their partnership would help enable the world’s first authorised covid-19 vaccine and mark a turning point in the global pandemic.
Such collaboration is characteristic of Canada’s life sciences sector. Across the country, investor conferences and industry gatherings convene life sciences leaders under one roof. BIOTECanada in Ottawa is an association representing the country’s more than 250 biotech companies and is a catalyst for global conferences and the in-person collaboration that leads to treatments for patients all over the globe.
With increasing venture capital and government support, Canadian life sciences firms are leading areas of study such as gene therapy and regenerative medicine. These areas were already the focus of most of the country’s pharmaceutical research, but increased funding is jettisoning the work even farther forward.
STEM talent
The strength of Canadian STEM talent has been buttressed by government support with policies designed to fast-track immigration for highly skilled workers as well as increasing quotas for permanent residency.
Government funding helped to build a bio-manufacturing campus in Ontario’s McMaster University, while over in Québec, millions of Canadian dollars went towards founding a world-leading, plant-based vaccine development facility.
The country’s manufacturing capabilities are boosted by investment in the underlying innovation. More than $2.2bn CAD has been invested into a biomedical research fund that also supports company creation, scale-up and training. New research facilities and start-up accelerators have turned Halifax, Québec, Montréal, Ottawa, and Toronto into global life sciences hubs with a global pedigree. Each of these cities is an important node in a global life sciences market.